Open Access

A novel ARMS-based assay for the quantification of EGFR mutations in patients with lung adenocarcinoma

  • Authors:
    • Yazhen Zhu
    • Zhiwei Guo
    • Ying Liu
    • Xiyun Zheng
    • Guohua Yang
    • Guangjuan Zheng
  • View Affiliations

  • Published online on: December 21, 2017     https://doi.org/10.3892/ol.2017.7679
  • Pages: 2905-2912
  • Copyright: © Zhu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Quantification of epidermal growth factor receptor (EGFR) mutations is important for the prediction of tyrosine kinase inhibitor (TKI) efficacy in patients with non‑small cell lung cancer (NSCLC). However, clinicians lack a sensitive and convenient method to quantify EGFR mutant abundance. The present study introduces a novel method, namely amplification refractory mutation system (ARMS)‑Plus, for the quantitative analysis of EGFR exon 19 deletion (19Del), L858R and T790M mutations. Formalin‑fixed paraffin‑embedded tumor samples were collected from 77 patients with lung adenocarcinoma. DNA was extracted and analyzed for EGFR mutations using ARMS‑Plus. The performance of ARMS‑Plus was then compared with that of conventional ARMS‑polymerase chain reaction (ARMS‑PCR) and droplet digital PCR (ddPCR). The results demonstrated that the concordance rate of EGFR mutation testing between ARMS‑Plus and ddPCR was 98.7% (76/77, Kappa=0.9739). 19Del and L858R mutations were detected in 23 and 12 patients, respectively. There was a significant difference between ARMS‑Plus and ddPCR in the evaluation of 19Del mutant abundance (P=0.0002); however, not in that of L858R mutant abundance (P=0.7334). The ARMS‑Plus results in L858R mutant abundance were concordant with that of ddPCR (R2=0.8081). These results indicated that the sensitivity and specificity of ARMS‑Plus in identifying EGFR mutations were similar to that of ddPCR. For quantitative analysis, the results of ARMS‑Plus in evaluating L858R mutant abundance revealed a positive correlation with the ddPCR results. Thus, ARMS‑Plus provides an alternative method, which is reliable and cost‑effective, to quantify EGFR mutations and thereby, aid treatment decisions in patients with lung adenocarcinoma.
View Figures
View References

Related Articles

Journal Cover

March-2018
Volume 15 Issue 3

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Zhu Y, Guo Z, Liu Y, Zheng X, Yang G and Zheng G: A novel ARMS-based assay for the quantification of EGFR mutations in patients with lung adenocarcinoma. Oncol Lett 15: 2905-2912, 2018
APA
Zhu, Y., Guo, Z., Liu, Y., Zheng, X., Yang, G., & Zheng, G. (2018). A novel ARMS-based assay for the quantification of EGFR mutations in patients with lung adenocarcinoma. Oncology Letters, 15, 2905-2912. https://doi.org/10.3892/ol.2017.7679
MLA
Zhu, Y., Guo, Z., Liu, Y., Zheng, X., Yang, G., Zheng, G."A novel ARMS-based assay for the quantification of EGFR mutations in patients with lung adenocarcinoma". Oncology Letters 15.3 (2018): 2905-2912.
Chicago
Zhu, Y., Guo, Z., Liu, Y., Zheng, X., Yang, G., Zheng, G."A novel ARMS-based assay for the quantification of EGFR mutations in patients with lung adenocarcinoma". Oncology Letters 15, no. 3 (2018): 2905-2912. https://doi.org/10.3892/ol.2017.7679